Johnson & Johnson Reports Phase 3 extension Data for Blinatumomab in Cystic fibrosis

Johnson & Johnson today announced Phase 3 extension results for blinatumomab in patients with cystic fibrosis. The study demonstrated that blinatumomab demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of cystic fibrosis and support the continued development of blinatumomab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.